Last reviewed · How we verify
NCT07231757
The RADIANCE CED Study
trial testing Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System) in Hypertension in 1,000 participants. Currently enrolling.
31 December 2029
Quick facts
| Lead sponsor | ReCor Medical, Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 21 November 2025 |
| Primary completion | 31 December 2029 |
| Estimated completion | 31 December 2031 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System)
Conditions studied
- Hypertension — all drugs for Hypertension →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
- Vascular Diseases — all drugs for Vascular Diseases →
Sponsor
ReCor Medical, Inc.
Who can join
65 and older, any sex, with Hypertension or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The RADIANCE CED study is a prospective observational study designed to evaluate the long-term effectiveness of ultrasound renal denervation in lowering blood pressure among patients with uncontrolled hypertension. Data will be collected from electronic health records (EHRs) of Medicare-eligible patients to support generalizability of outcomes to the broader Medicare population. Individual hospital enrollment is not required for this study and IRB exemption has been received by sponsor.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07231757
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other ReCor Medical, Inc. trials
Trials by the same sponsor.
- NCT05017935 — RADIANCE Continued Access Protocol · NA · active not recruiting
- NCT05027685 — The "Global Paradise System" Registry · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07231757 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ReCor Medical, Inc.
- Last refreshed: 9 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07231757.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing